PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacific Bio (PACB) Reports In-Line Q4 EPS
February 16, 2023 4:04 PM ESTPacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $27.4 million versus the consensus estimate of $26.59 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
... More